The Devyser blog

One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...

Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...

Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and...

For many laboratories, CFTR testing is not an occasional add-on. It is part of a routine,...

Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...

Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...

Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...

Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...

Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...

Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...

Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...